<DOC>
	<DOCNO>NCT01148680</DOCNO>
	<brief_summary>Efficacy pancreatic islet transplantation 6 month compare intensive insulin therapy 2 category patient : patient unstable diabetes patient underwent kidney transplantation .</brief_summary>
	<brief_title>Trial Comparing Metabolic Efficiency Islet Graft Intensive Insulin Therapy Type 1 Diabetes 's Treatment</brief_title>
	<detailed_description>Efficacy pancreatic islet transplantation 6 month compare intensive insulin therapy 2 category patient : patient unstable type 1 diabetes versus patient unstable type 1 diabetes underwent kidney transplantation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patient type 1 diabetes Cpeptide negative diabetes Diabetes duration &gt; 5 year No residual insulin secretion ( plasmatic basal stimulate Cpeptide &lt; 0.3 ng/ml ) HbA1c consider acceptable selection committee Insulin need &lt; 0.85 IU/kg/day Islet cell infusion kidney graft Patient terminal renal failure functional kidney graft least 6 month ( creatinine clearance great equal 35 ml/min ) Patient whose glycaemic control obtain insulin therapy could threaten kidney graft survival and/or significantly alter quality life . This situation assess diabetologist Islet cell infusion : patient major glycaemic variability despite proper intensive insulin therapy , closely monitored diabetologist . Poor glucose control , assessed diabetologist , endanger patient 's life and/or significantly alters personal , social , professional family quality life . At least one criterion must fulfil : Hypoglycaemia unawareness , blood glucose level &lt; 3mmol/L 0.54 mg/L At least 2 severe hypoglycaemia event ( define necessity third party 's assistance ) per year ketoacidosis require patient 's hospitalization last year . Impairment quality life lifethreat patient person , progressive complication despite optimal insulin therapy Social Security membership benefit Social Welfare Age &lt; 18 &gt; 65 Diabetes duration &lt; 5 year Criteria specifically related islet intraportal injection procedure : hemostasis problem , haemoglobin level &lt; 11g/dL woman &lt; 12g/dL men , abnormality complete blood count , document liver pathology ( alkaline phosphatase , gamma GT , transaminases level twice normal value ) ; pancreatitis history , gallbladder stone could potentially migrate ; HLA hyperimmunisation ( PRA &gt; 20 % ) . Criteria related diabetes complication : Nonstabilized proliferate diabetic retinopathy Creatininaemia &gt; 16 mg/dL Exclusion criterion nonspecifically related islet infusion : evolutive vascular disease , evolutive cardiopathy ( especially myocardial infarction le 6 month ago , cerebrovascular stroke less 6 month ago , evolutive arteritis trophic disorder ) ; systemic infection include hepatitis C HIV ; leuconeutropenia ; thrombocytopenia , nonstabilized neoplastic pathology ; pregnancy project pregnancy within next 24 month ; poor therapeutic compliance Criteria relate immunosuppressive protocol : renal failure ( glomerular filtration &lt; 35 ml/min/1.73 m² ) and/or proteinuria &gt; 0.5 g/24h ; nontreated hyperlipidemia ( LDLC &gt; 130 mg/dL ) ; blood pressure &gt; 160/100 mmHg Clinical insulin resistance : assessed patient 's weight , BMI exogenous insulin requirement ( BMI &gt; 30 kg/m² insulin dose &gt; 0.85 UI/kg/day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Islet Cell Transplantation</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
</DOC>